|Day Low/High||121.14 / 123.09|
|52 Wk Low/High||72.05 / 158.80|
The action is a bit choppy as market players figure out there's time for a little rest before running more.
These trades may not be playable today, but they are setting up for the near future.
With this emotional level out of the way, maybe logic can apply again.
Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.
It's a flipper's market, and some small-caps and mortgage plays are on the move.
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
I don't like the overall market action, so I'm focusing on these individual stocks today.
Traders who were ready to fade the open are now scrambling for position.
Make the necessary defensive moves and take those stops, even if it's painful.
There is nothing better than digging for undiscovered gems and buying them.
Adam Feuerstein, senior columnist for TheStreet, says Sarepta Therapeutics is the next big thing to watch in biotech.